Baker Ellis Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Baker Ellis Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$827K	Sell	1,852 -100	-5%	-$46.6K	0.1%	126
2025 Q4	$885K	Hold	1,952	–	–	0.11%	123
2025 Q3	$764K	Buy	1,952 +900	+86%	+$376K	0.09%	133
2025 Q2	$468K	Sell	1,052 -221	-17%	-$102K	0.06%	146
2025 Q1	$617K	Buy	1,273 +215	+20%	+$100K	0.09%	134
2024 Q4	$426K	Buy	1,058 +320	+43%	+$148K	0.06%	152
2024 Q3	$343K	Sell	738 -32	-4%	-$15.4K	0.05%	177
2024 Q2	$361K	Buy	770 +160	+26%	+$69.4K	0.05%	162
2024 Q1	$255K	Buy	+610	New	+$258K	0.04%	191

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baker Ellis Asset Management's VRTX Position: Q1 2026 in Review

Baker Ellis Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 5.1% in Q1 2026, selling an estimated $46.6K and leaving 1,852 shares worth $827K. The position accounts for 0.1% of the portfolio, ranked #126.

Baker Ellis Asset Management first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $885K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Baker Ellis Asset Management held 1,852 shares of Vertex Pharmaceuticals worth $827K as of Q1 2026.
Baker Ellis Asset Management sold 100 Vertex Pharmaceuticals shares in Q1 2026, an estimated $46.6K.
Vertex Pharmaceuticals made up 0.1% of Baker Ellis Asset Management's portfolio in Q1 2026, its #126 holding.
Baker Ellis Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Baker Ellis Asset Management's Vertex Pharmaceuticals position peaked at $885K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Baker Ellis Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.